Could a common supplement help a rare disease? new study begins safety check
NCT ID NCT07572825
First seen May 08, 2026 · Last updated May 18, 2026 · Updated 1 time
Summary
This early-stage study will test the safety of the dietary supplement NMN in 8 people aged 4 and older who have a rare genetic condition called DHDDS-CDG. The main goal is to see if NMN is safe and tolerable, and to gather information that may help doctors decide whether to recommend it in the future. The study does not aim to cure or treat the disease directly, but to build knowledge about using NMN in this specific group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL DISORDER OF GLYCOSYLATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.